home / stock / arct / arct news

ARCT News and Press, Arcturus Therapeutics Ltd. From 08/08/23

Stock Information
Company Name: Arcturus Therapeutics Ltd.
Stock Symbol: ARCT
Market: NASDAQ
Website: arcturusrx.com
Menu
ARCT ARCT Quote ARCT Short ARCT News ARCT Articles ARCT Message Board
Get ARCT Alerts

News, Short Squeeze, Breakout and More Instantly...
ARCT - Bright Minds, Bionomics top healthcare gainers; Vistagen, AxoGen among losers

2023-08-08 10:21:19 ET Gainers: Bright Minds Biosciences ( DRUG ) +62% . Bionomics ( BNOX ) +24% . Novo Nordisk ( NVO ) +18% . Quanterix ( QTRX ) +17% . Tilray Brands ( TLRY ) +18% . Losers: Vistagen Therapeutics ( VTGN ...
ARCT - Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Call Transcript

2023-08-07 20:18:04 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Neda Safarzadeh - VP, Head IR, Public Relations and Marketing Joseph Payne - President and CEO Andy Sassine - CFO ...

ARCT - Arcturus Therapeutics GAAP EPS of -$1.98 misses by $1.81, revenue of $10.52M misses by $38.81M

2023-08-07 16:17:08 ET Arcturus Therapeutics press release ( NASDAQ: ARCT ): Q2 GAAP EPS of -$1.98 misses by $1.81 . Revenue of $10.52M (-61.2% Y/Y) misses by $38.81M . Cash, cash equivalents and restricted cash were $380.6 million as of June 30, 2023 and $394....

ARCT - Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress

ARCT-154 Phase 3 COVID-19 booster trial achieved primary endpoint demonstrating strong immune response and favorable safety profile Meiji Seika Pharma submitted ARCT-154 New Drug Application in Japan New ARCT-154 booster clinical data demonstrate one-year durability across a panel...
ARCT - Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023

Arcturus to present at the Canaccord Genuity 43 rd Annual Growth Conference , August 9, 2023 Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the dev...

ARCT - 3 Biotech Stocks for Getting Rich in 2023

2023-07-18 06:22:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry’s research and development. Large biotech companies such as Johnson and Johnso...

ARCT - PainReform, Acadia top healthcare gainers; Theseus, Galmed among losers

2023-07-14 10:01:23 ET Gainers: PainReform ( PRFX ) +112% . Acadia Pharmaceuticals ( ACAD ) +15% . Nutriband ( NTRB ) +14% . Arcturus Therapeutics ( ARCT ) +10% . Exicure ( XCUR ) +7% . Losers: Theseus Pharmaceuticals ( ...
ARCT - Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race

2023-06-26 13:40:30 ET Summary Arcturus Therapeutics is developing mRNA medicines and vaccines for infectious diseases and rare disorders, with a focus on their ARCT-810 candidate for ornithine transcarbamylase deficiency. The company reported strong Q1 2023 financial results, wit...

ARCT - ARCT, ENVX and XERS are among after hour movers

2023-06-15 17:38:38 ET Gainers: Adobe  ( ADBE ) +5% . Arcturus Therapeutics  ( ARCT ) +5% . Xeris Biopharma Holdings ( XERS ) +4% . Castle Biosciences ( CSTL ) +4% . Enovix Corporation ( ENVX ) +4% . Losers: Mil...

ARCT - Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today ann...
Previous 10 Next 10